Evidence map›Paper›PMID 37883093›Full record

ArticleInvestigative ophthalmology & visual science2023

Retinal Dystrophy Associated With RLBP1 Retinitis Pigmentosa: A Five-Year Prospective Natural History Study.

Marie Burstedt, James H Whelan, Jane S Green, Karen Holopigian, Claudio Spera, Erin Greco, Jean-Yves Deslandes, Michael Wald, Cynthia Grosskreutz, Xiao Ni and 6 more

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Marie BurstedtClinical Sciences/Ophthalmology, University of Umeå, Umeå, Sweden.
James H WhelanMemorial University of Newfoundland, St John's, Newfoundland, Canada.
Jane S GreenMemorial University of Newfoundland, St John's, Newfoundland, Canada.
Karen HolopigianNovartis Institutes for BioMedical Research, East Hanover, New Jersey, United States.
Claudio SperaNovartis Pharma AG, Basel, Switzerland.
Erin GrecoNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Jean-Yves DeslandesNovartis Institutes for BioMedical Research, East Hanover, New Jersey, United States.
Michael WaldNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Cynthia GrosskreutzNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Xiao NiNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Guillaume NormandNovartis Institutes for BioMedical Research, East Hanover, New Jersey, United States.
Michael MakerNovartis Institutes for BioMedical Research, East Hanover, New Jersey, United States.
Arnaud CharilNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Michael RosolNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Yunsheng HeNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Kalliopi StasiNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States.
Boston Biomedical Research Institute · USNovartis (United States) · USMemorial University of Newfoundland · CANovartis (Switzerland) · CHUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To assess the progression in functional and structural measures over a five-year period in patients with retinal dystrophy caused by RLBP1 gene mutation. Methods: This prospective, noninterventional study included patients with biallelic RLBP1 mutations from two clinical sites in Sweden and Canada. Key assessments included ocular examinations, visual functional measures (best-corrected visual acuity [BCVA], contrast sensitivity [CS], dark-adaptation [DA] kinetics up to six hours for two wavelengths [450 and 632 nm], Humphrey visual fields [HVF], full-field flicker electroretinograms), and structural ocular assessments. Results: Of the 45 patients enrolled, 38 completed the full five years of follow-up. At baseline, patients had BCVA ranging from -0.2 to 1.3 logMAR, poor CS, HVF defects, and prominent thinning in central foveal thickness. All patients had extremely prolonged DA rod recovery of approximately six hours at both wavelengths. The test-retest repeatability was high across all anatomic and functional endpoints. Cross-sectionally, poorer VA was associated with older age (right eye, correlation coefficient [CC]: 0.606; left eye, CC: -0.578; P < 0.001) and HVF MD values decreased with age (right eye, CC: -0.672, left eye, CC: -0.654; P < 0.001). However, no major changes in functional or structural measures were noted longitudinally over the five-year period. Conclusions: This natural history study, which is the first study to monitor patients with RLBP1 RD for five years, showed that severely delayed DA sensitivity recovery, a characteristic feature of this disease, was observed in all patients across all age groups (17-69 years), making it a potentially suitable efficacy assessment for gene therapy treatment in this patient population.

Indexed as

Retinal DystrophiesRetinitis PigmentosaAdolescentAdultAgedHumansMiddle AgedProspective StudiesVisual AcuityVisual FieldsYoung Adult

Identifiers

PMID37883093
PMCPMC10615144
OpenAlexW4387949581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.